{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001076","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.422708+00:00","generated_at":"2026-05-16T11:32:09.762729+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses","bullets":["ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.","PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.","At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.","Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.","Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001076","json":"https://secwatch.observer/filing/0001104659-26-001076.json","markdown":"https://secwatch.observer/filing/0001104659-26-001076.md","text":"https://secwatch.observer/filing/0001104659-26-001076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/0001104659-26-001076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:32:09.762729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}